Biocryst Pharmaceuticals (BCRX) Notes Payables (2014 - 2021)

Biocryst Pharmaceuticals' Notes Payables history runs 8 years deep, the most recent figure standing at $30.0 million for Q3 2021.

• Quarterly Notes Payables changed 0.37% year-over-year to $30.0 million in Q3 2021, while the trailing twelve-month figure through Sep 2021 was $30.0 million (changed 0.37% YoY) and the FY2020 annual result came in at $30.0 million, up 1.49% from the prior year.
• Notes Payables was $30.0 million for Q3 2021 at Biocryst Pharmaceuticals, roughly flat from $30.0 million in the prior quarter.
• Across five years, Notes Payables topped out at $30.0 million in Q4 2020 and bottomed at $28.4 million in Q1 2017.
• A 5-year average of $29.3 million and a median of $29.3 million in 2019 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2017 — Notes Payables gained 1.57% — and 2021, when it climbed 0.37%.
• Biocryst Pharmaceuticals' Notes Payables stood at $28.7 million in 2017, then increased by 1.53% to $29.1 million in 2018, then gained by 1.51% to $29.6 million in 2019, then gained by 1.49% to $30.0 million in 2020, then changed by 0.0% to $30.0 million in 2021.
• Business Quant data shows BCRX's Notes Payables at $30.0 million in Q3 2021, $30.0 million in Q2 2021, and $30.0 million in Q1 2021.